Nivolumab + Paclitaxel + Cetuximab + Paclitaxel
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Conditions
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Trial Timeline
Jun 3, 2020 → Mar 21, 2024
NCT ID
NCT04282109About Nivolumab + Paclitaxel + Cetuximab + Paclitaxel
Nivolumab + Paclitaxel + Cetuximab + Paclitaxel is a phase 2 stage product being developed by Bristol Myers Squibb for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04282109. Target conditions include Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04282109 | Phase 2 | Completed |
Competing Products
4 competing products in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Drug Combination Therapy | Sun Pharmaceutical | Phase 2 | 52 |
| MEDI4736 + Tremelimumab + MEDI4736 + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| pepinemab + pembrolizumab | Merck | Phase 1/2 | 41 |
| Pembrolizumab + Cisplatin + Carboplatin + Gemcitabine | Merck | Phase 2 | 52 |